======= PFKP =======
== Gene Information ==
* **Official Symbol**: PFKP
* **Official Name**: phosphofructokinase, platelet
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=5214|5214]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q01813|Q01813]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PFKP&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PFKP|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/171840|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a member of the phosphofructokinase A protein family. The encoded enzyme is the platelet-specific isoform of phosphofructokinase and plays a key role in glycolysis regulation. This gene may play a role in metabolic reprogramming in some cancers, including clear cell renal cell carcinomas, and cancer of the bladder, breast, and lung. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016].
* **UniProt Summary**: Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis.
|PFK|
|6-phosphofructokinase complex|
|6-phosphofructokinase activity|
|fructose-6-phosphate binding|
|fructose 6-phosphate metabolic process|
|fructose 1,6-bisphosphate metabolic process|
|AMP binding|
|monosaccharide binding|
|NADH regeneration|
|glucose catabolic process to pyruvate|
|canonical glycolysis|
|glycolytic process through glucose-6-phosphate|
|glycolytic process through fructose-6-phosphate|
|glucose catabolic process|
|NADH metabolic process|
|glycolytic process|
|ATP generation from ADP|
|NAD metabolic process|
|ADP metabolic process|
|hexose catabolic process|
|nucleoside diphosphate phosphorylation|
|purine ribonucleoside diphosphate metabolic process|
|nucleotide phosphorylation|
|purine nucleoside diphosphate metabolic process|
|monosaccharide catabolic process|
|ribonucleoside diphosphate metabolic process|
|pyruvate metabolic process|
|nucleoside diphosphate metabolic process|
|protein homotetramerization|
|response to leukemia inhibitory factor|
|cellular response to leukemia inhibitory factor|
|glucose metabolic process|
|carbohydrate catabolic process|
|protein tetramerization|
|hexose metabolic process|
|monosaccharide metabolic process|
|ATP metabolic process|
|protein-containing complex binding|
|cadherin binding|
|purine ribonucleotide metabolic process|
|ribonucleotide metabolic process|
|purine nucleotide metabolic process|
|ribose phosphate metabolic process|
|protein homooligomerization|
|purine-containing compound metabolic process|
|generation of precursor metabolites and energy|
|small molecule catabolic process|
|nucleotide metabolic process|
|nucleoside phosphate metabolic process|
|carbohydrate metabolic process|
|protein complex oligomerization|
|monocarboxylic acid metabolic process|
|nucleobase-containing small molecule metabolic process|
|organophosphate metabolic process|
|carboxylic acid metabolic process|
|oxidation-reduction process|
|oxoacid metabolic process|
|cellular response to cytokine stimulus|
|organic acid metabolic process|
|carbohydrate derivative metabolic process|
|identical protein binding|
|response to cytokine|
|phosphorylation|
|ATP binding|
|protein-containing complex assembly|
|small molecule metabolic process|
|organic substance catabolic process|
|protein-containing complex subunit organization|
|membrane|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp439|QNZ 0.01μM R08 exp439]]|-3|
|[[:results:exp25|Oligomycin-A 2μM R00 exp25]]|-2.25|
|[[:results:exp431|Rotenone 0.07μM R08 exp431]]|-2.23|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|-2.05|
|[[:results:exp191|Hypoxia 5%O2 R04 exp191]]|-1.97|
|[[:results:exp210|LB-100 2μM R05 exp210]]|1.76|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|1.76|
|[[:results:exp270|Campthothecin 0.001μM R06 exp270]]|1.78|
|[[:results:exp334|All-trans-Retinoic-Acid 40μM R07 exp334]]|1.8|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|1.8|
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|1.8|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|1.86|
|[[:results:exp415|Trichostatin-A 0.06μM R07 exp415]]|1.86|
|[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|1.87|
|[[:results:exp312|2-Methoxyestradiol 0.55 to 1μM on day4 R07 exp312]]|1.88|
|[[:results:exp247|UM0130462 0.025 to 0.035μM day4 R05 exp247]]|1.88|
|[[:results:exp510|Nicotine 3000μM R08 exp510]]|1.89|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|1.9|
|[[:results:exp319|ABT-702 5μM plus Dimethyloxaloylglycine 11μM R07 exp319]]|1.92|
|[[:results:exp355|Dinaciclib 0.007μM R07 exp355]]|1.94|
|[[:results:exp517|Quercetin 20μM R08 exp517]]|1.97|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|2.04|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|2.07|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|2.09|
|[[:results:exp81|Selumetinib 20μM R02 exp81]]|2.12|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|2.18|
|[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|2.23|
|[[:results:exp103|Taxol 0.004μM R03 exp103]]|2.24|
|[[:results:exp461|BS-181 20μM R08 exp461]]|2.3|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|2.32|
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|2.35|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|2.41|
|[[:results:exp216|Erlotinib 10μM R05 exp216]]|2.42|
|[[:results:exp356|Docosahexaenoic-acid 50μM R07 exp356]]|2.48|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|2.56|
|[[:results:exp175|3-Bromopyruvate 7μM R04 exp175]]|2.61|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|2.85|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|3.11|
|[[:results:exp79|Q15 2.7μM R02 exp79]]|3.39|
|[[:results:exp214|2-Deoxy-D-glucose 800μM R05 exp214]]|7.65|
^Gene^Correlation^
|[[:human genes:h:hk2|HK2]]|0.709|
|[[:human genes:h:hk1|HK1]]|0.6|
|[[:human genes:s:slc2a1|SLC2A1]]|0.599|
|[[:human genes:g:gpi|GPI]]|0.512|
|[[:human genes:p:pgp|PGP]]|0.512|
|[[:human genes:m:mlf2|MLF2]]|0.479|
|[[:human genes:p:pgls|PGLS]]|0.461|
|[[:human genes:a:ahcyl1|AHCYL1]]|0.454|
|[[:human genes:g:got1|GOT1]]|0.439|
|[[:human genes:s:slc16a1|SLC16A1]]|0.428|
|[[:human genes:v:vdac1|VDAC1]]|0.422|
|[[:human genes:s:snx27|SNX27]]|0.408|
Global Fraction of Cell Lines Where Essential: 1/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|1/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 674
* **Expression level (log2 read counts)**: 7.3
{{:chemogenomics:nalm6 dist.png?nolink |}}